Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease
© 2023 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC..
INTRODUCTION: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. During registration and settling reimbursement in Europe, it could be requested on a compassionate use basis, for patients with advanced lung disease (ppFEV1 < 40).
AIM: The aim of this study is to evaluate 2 years of experience with the clinical and radiological response of ELE/TEZ/IVA in pwCF in a compassionate use setting.
METHODS: pwCF who started ELE/TEZ/IVA in a compassionate use setting were prospectively followed with assessment of spirometry, BMI, chest CT, CFQ-R and sweat chloride concentration (SCC) before start and after 3 months. Furthermore, spirometry, sputum cultures, and BMI were repeated after 1, 6, 12, 18, and 24 months.
RESULTS: Eighteen patients were eligible for this evaluation, nine with F508del/F508del genotype (eight of whom were using dual CFTR modulators) and nine with F508del/minimal function mutation. After 3 months, mean change in SCC was -44.9 (p ≤ 0.001), together with significant improvement in CT (change in Brody score: -28.27 p ≤ 0.001) and CFQ-R results (change in respiratory domain: +18.8, p = 0.002). After 24 months, ppFEV1 change was +8.89 (p = 0.002), BMI had improved by +1.53 kg/m2 (p ≤ 0.001) and exacerbation rate declined from 5.94 in 24 months before start to 1.17 (p ≤ 0.001) in the 24 months after.
CONCLUSION: pwCF with advanced lung disease experience relevant clinical benefit after 2 years of treatment with ELE/TEZ/IVA in a compassionate use setting. Structural lung damage, quality of life, exacerbation rate, and BMI improved significantly with treatment. Gain in ppFEV1 is lower compared to the phase III trials that included younger patients with moderately affected lung function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Pediatric pulmonology - 58(2023), 8 vom: 01. Aug., Seite 2317-2322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aalbers, Bente L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.07.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ppul.26486 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357247965 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357247965 | ||
| 003 | DE-627 | ||
| 005 | 20231226072156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ppul.26486 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357247965 | ||
| 035 | |a (NLM)37222401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aalbers, Bente L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC. | ||
| 520 | |a INTRODUCTION: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. During registration and settling reimbursement in Europe, it could be requested on a compassionate use basis, for patients with advanced lung disease (ppFEV1 < 40) | ||
| 520 | |a AIM: The aim of this study is to evaluate 2 years of experience with the clinical and radiological response of ELE/TEZ/IVA in pwCF in a compassionate use setting | ||
| 520 | |a METHODS: pwCF who started ELE/TEZ/IVA in a compassionate use setting were prospectively followed with assessment of spirometry, BMI, chest CT, CFQ-R and sweat chloride concentration (SCC) before start and after 3 months. Furthermore, spirometry, sputum cultures, and BMI were repeated after 1, 6, 12, 18, and 24 months | ||
| 520 | |a RESULTS: Eighteen patients were eligible for this evaluation, nine with F508del/F508del genotype (eight of whom were using dual CFTR modulators) and nine with F508del/minimal function mutation. After 3 months, mean change in SCC was -44.9 (p ≤ 0.001), together with significant improvement in CT (change in Brody score: -28.27 p ≤ 0.001) and CFQ-R results (change in respiratory domain: +18.8, p = 0.002). After 24 months, ppFEV1 change was +8.89 (p = 0.002), BMI had improved by +1.53 kg/m2 (p ≤ 0.001) and exacerbation rate declined from 5.94 in 24 months before start to 1.17 (p ≤ 0.001) in the 24 months after | ||
| 520 | |a CONCLUSION: pwCF with advanced lung disease experience relevant clinical benefit after 2 years of treatment with ELE/TEZ/IVA in a compassionate use setting. Structural lung damage, quality of life, exacerbation rate, and BMI improved significantly with treatment. Gain in ppFEV1 is lower compared to the phase III trials that included younger patients with moderately affected lung function | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brody score | |
| 650 | 4 | |a CFTR modulators | |
| 650 | 4 | |a chest CT | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a quality of life | |
| 650 | 7 | |a Aminophenols |2 NLM | |
| 650 | 7 | |a Benzodioxoles |2 NLM | |
| 650 | 7 | |a Chloride Channel Agonists |2 NLM | |
| 650 | 7 | |a Cystic Fibrosis Transmembrane Conductance Regulator |2 NLM | |
| 650 | 7 | |a 126880-72-6 |2 NLM | |
| 650 | 7 | |a elexacaftor |2 NLM | |
| 650 | 7 | |a RRN67GMB0V |2 NLM | |
| 650 | 7 | |a ivacaftor |2 NLM | |
| 650 | 7 | |a 1Y740ILL1Z |2 NLM | |
| 650 | 7 | |a tezacaftor |2 NLM | |
| 700 | 1 | |a Mohamed Hoesein, Firdaus A A |e verfasserin |4 aut | |
| 700 | 1 | |a Hofland, Regina W |e verfasserin |4 aut | |
| 700 | 1 | |a Bronsveld, Inez |e verfasserin |4 aut | |
| 700 | 1 | |a Kruijswijk, Marian A |e verfasserin |4 aut | |
| 700 | 1 | |a Schotman, Suzan |e verfasserin |4 aut | |
| 700 | 1 | |a Slingerland, Corlien W |e verfasserin |4 aut | |
| 700 | 1 | |a Panhuis, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a van der Ent, C Kors |e verfasserin |4 aut | |
| 700 | 1 | |a Heijerman, Harry G M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric pulmonology |d 1993 |g 58(2023), 8 vom: 01. Aug., Seite 2317-2322 |w (DE-627)NLM012888230 |x 1099-0496 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:2317-2322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ppul.26486 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2023 |e 8 |b 01 |c 08 |h 2317-2322 | ||